Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies

Takeda Pharmaceutical saw its group operating profit nearly double in April-September largely in a rebound from a year ago, when it incurred purchase accounting and integration expenses tied to its Shire acquisition, but also thanks to cost synergies following the...read more